Sounds like a whole lotta "still no cure" talk. Like you said, everyone's immune system is different, so the only way to get a more certain, across-the-board response is to remove the damn virus.. don't see any other way than for crispr to have success... if that doesn't happen, then it's gonna be a rough ride for some of us.
How many and over what time is a guessing game really. As I indicated (page 6 of this thread) when your immune system receives the vaccine and your own immune basis will matter. You're constantly evolving to what its detecting and responding too. Some people don't have antibodies one month while next they have a ton to a particular protein.
Genocea showed that asymptomatic people recognize on average almost double the antigens that symptomatic people do. The question then is a live vaccine going to beat an UV inactivated vaccine (and/or with an adjuvant) in producing antibodies and t-cells to the antigens you were presumably missing anyways? Is it because your immune system is seeing a flood of it that it will recognize it as opposed to an outbreak? hmmm
I don't see how disclosing the location would be a benefit to the company but to the contrary a possible liability.. I believe it is pointing to trials in the us not to say there cant be a simultaneous trials and possibly commercial sales in another country if the company allows it happens all the time with new drugs ..the FDA sure isn't going to stop commercial sales in parts of the world where research is able to be expedited... Supply and demand and most importantly dollar signs
Don't be dissuaded too much... results will vary
Too hard to say:
The other live attenuated vaccine that was tested in humans ICP10 delta PK in around 38 people took 3 injections and some 36% reported being OB free after a year. I would imagine his live vaccine may have similar results.
Well then, he's making the assumption that the protective immunity generated from HSV is equivalent to when someone or some animal already has HSV1/2. His published literature does not explore therapeutic potential in animals, only protective immunity. See: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116091
As I stated, HSV amplicon research already proves the assumption/or his theory that prophylactic and therapeutic vaccination to be equivalent, as wrong. Granted it will presumably be better, but nowhere near x40-100.
Theravax‾² vaccine. RVx is planning clinical trials of our live-attenuated therapeutic HSV-2 vaccine, which the published literature indicates is about 40 – 100 times more effective than any of HSV-2 subunit type vaccines developed over the past 30 years.